drugset
Drugs / TIPLIMOTIDE
last change Apr 2005 re-read 3 minutes ago

TIPLIMOTIDE

also known as NBI-5788 · Tiplimotida

Peptide

Developed for
multiple sclerosis
Investigated by
Immune Tolerance Network (ITN) · Neurocrine Biosciences

Trials 1

today NCT00079495 · Ph 2
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00079495 Jul 2003 → Apr 2005 multiple sclerosis Neurocrine Biosciences Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2003-07-28 Neurocrine Biosciences Neurocrine Biosciences Announces Initiation of Phase II Clinical Trial With NBI-5788 for Multiple Sclerosis gcs-web.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TIPLIMOTIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL2108869 ↗
Known as NBI-5788 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00079495 ↗
Known as Tiplimotida ChEMBL registry synonym — accepted as the source's own label CHEMBL2108869 ↗
Modality Peptide “Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)” NCT00079495 ↗